Pharma Stocks Outlook for the week (06 - 10.08.2012)

Apr-Jun earnings are seen influencing action in pharmaceutical stocks next
week as many companies are set to detail their quarterly numbers in the
coming week. Bullish on Divi's Laboratories and Cadila Healthcare that are
reporting their Apr-Jun results on Saturday and Monday, respectively.
Investors would also be looking at Aurobindo Pharma's earnings that will be
detailed Tuesday. Stocks of Ranbaxy Laboratories are likely to gain next
week on talks the company is set to launch a diabetes-treating drug Actos
in the US market by mid-August. The company, in 2010, had resolved a patent
litigation with Japan-based company Takeda Pharmaceutical Co whereby the
latter had granted a non-exclusive royalty free licence to its US patents
covering Actos to Ranbaxy. Sun Pharmaceutical Industries' stocks are also
seen gaining momentum next week on the company's likely acquisition of
UK-based pharmaceutical company Stada.
However, given the economic crisis in the eurozone region, it would be hard
to turn the company around, which should be negative for Sun Pharmaceutical
in the long run. So far, pharmaceutical companies have reported
exceptionally well numbers in Apr-Jun with around 20% growth in domestic
businesses and over 40% growth in the US businesses. Therefore,
pharmaceutical stocks are seen outperforming the benchmark indices by
around 10% over the next one month. However, stocks of Glenmark
Pharmaceuticals may fall next week as the company's consolidated net profit
for Apr-Jun fell sharply to 782.75 mln rupees from 2.08 bln rupees last
year. This figure is lower than the 1-bln-rupee net profit the Street had
expected, as the company suffered a marked-to-market loss of 550 mln rupees.


 By RUPEE DESK  [email protected]

-- 
You received this message because you are subscribed to the Google Groups 
"Kences1- Rupeedesk" group.
To post to this group, send email to [email protected].
To unsubscribe from this group, send email to 
[email protected].
For more options, visit this group at 
http://groups.google.com/group/kences1?hl=en.

Reply via email to